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OBJECTIVES: To update a previously published systematic literature review and
meta-analysis investigating the effectiveness of asthma self-management educa-
tion programs on health outcomes in children. METHODS: The updated search is
through June 2010 and included published meta-analysis or journals from MEDLINE,
EMBASE, and the Cochrane Central Register of Controlled Trials. All available Eng-
lish abstracts were reviewed and the full text was consulted as necessary to clarify
eligibility status. Eligible studies were randomized controlled trials or controlled
clinical trials that evaluated outcomes in children ages 2-18 years with a diagnosis
of asthma. Data were extracted on the study population, intervention types, sam-
ple size, sample size calculations, loss to follow-up, outcomes, andmethodological
quality of the studies. Datawere pooled using both fixed effects and randomeffects
models. Effect estimates were plotted in forest plots and heterogeneity was as-
sessed visually and statistically using the I2 statistic. All data were analyzed using
RevMan software. RESULTS: Preliminary results with the addition of several recent
studies suggested that educational programs for the self-management of asthma
in children were associated with modest to moderate improvement in several
outcomemeasures, such as themean number of emergency department visits (n
17 studies; SMD: 0.67; 95% CIs: 1.23, 0.11; I2  97%) and mean number of
hospitalizations (n 11 studies; SMD: 0.50; 95% CIs: 0.70, 0.29; I2  62%). The
results for random effects models were similar to fixed effects models.
CONCLUSIONS: Incorporating educational programs for self-management into the
routine care of children and adolescents with asthma may significantly improve
outcomes. This update will improve the power of small or inconclusive studies,
allowing for analysis of subgroup effects and the comparative effectiveness of
alternative strategies. Results are preliminary and a full update of the meta-anal-
ysis is forthcoming.
PRS34
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OBJECTIVES: Asthma, a chronic disease requires lifelong adherence to medication
and optimal self-management. Studies indicate that worldwide self-management
of asthma is poor and evidence-based suitable interventions are needed for asthma
control. The present study was conducted to investigate the pattern of self-man-
agement in asthmatic patients in Delhi, India. METHODS: Adult asthma patients
(n200) visiting emergency room (December 2008-December 2009) of a tertiary care
referral chest hospital for asthma exacerbation completed self-report question-
naire on self-management of asthma after stabilization.Written informed consent
from patients and ethical clearance from institute was obtained. Questionnaire
contained 51 questions having six domains: Socio-demographic profile, clinical
profile, morbidity and activities of living, access to care, asthma attack prevention
and emergency actions. RESULTS: Study population had 64% female, 51.5% be-
tween 30-40 year and 10% were illiterate. Patients were enrolled as asthma out-
patients in the study hospital for 5.44.4 years. All patients except one were pre-
scribed corticosteroidbeta2 agonist inhalers. Patients visiting ER and having
unscheduled visit to doctor at least twice in the previous 12monthswere 86.5% and
91% respectively. Patients were classified according to the disease severity as hav-
ing intermittent (17%) or persistent (83%) asthma. Majority of patients visited the
study hospital for usual source of treatment and in case of exacerbation. Not all
patients had meter dose inhalers at home. Only 2% patients were prescribed peak
flow meter and one patient reported using it regularly and keeping diary. No sta-
tistical difference was found in pattern of self-management by patients having
persistent or intermittent asthma. Except one, no patient had any written action
plan for treatment or for emergency. CONCLUSIONS: Findings revealed poor self-
management of asthma and lack of communication between doctor and patient.
Immediate action is needed to impart knowledge of self-management and written
action plan for asthma patients by physicians.
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OBJECTIVES: (1) To understand how multiple pharmacy use affects the ability to
compute pharmacy quality indicators (PQIs). (2) To determine the number of phar-
macies that have sufficient Medicaid claims to compute PQIs. METHODS: An ob-
servational cohort study of Mississippi Medicaid data for 2002 and 2004 was con-
ducted. Patients with medication claims related to each measure, continuously
enrolled, and without institutional care during the measurement year were eligi-
ble. The PQIs in the Pharmacy Quality Alliance ‘(PQA)-endorsed starter set’ were
computed at the patient level and aggregated to the pharmacy level by attributing
each beneficiary to the pharmacy that dispensed the most (and alternative criteria
of 50% and 75%) of their drugs for themeasure. Pharmacies with at least 30 eligible
members per measure were considered reliable. Additionally, the 2010 PQA test
measures (adherence to anticonvulsants and antiretrovirals, statin use with CAD,
asthma management) were evaluated. RESULTS: The majority of patients (three-
fourths) obtained over 90% of their diabetes and cardiovascular medications from
one pharmacy. Around 85% and 97% of the patients obtained over 75% and over
50% of theirmedications from a single pharmacy respectively. Only 55% of patients
received antiretroviral medications from a single pharmacy. For the adherence/
persistence measures, 6.3% to 65.3% of the pharmacies had reliable measures in
2002. 78.2% of the pharmacies could be included for the high-risk medications in
elderly measure and 2.7% of the pharmacies qualified for the CAD measure. Less
than 10 pharmacies qualified for the asthmamanagement and antiretroviral med-
ication adherence measures. A similar pattern was observed in 2004.
CONCLUSIONS: The attribution strategy proposed by PQA can bemademore strin-
gent without severely limiting the number of pharmacies with measures. Using a
pharmacy attribution criteria of 50% or 75% of fills from the same pharmacywill
result in more reliable PQI metrics.
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OBJECTIVES: To evaluate whether hospitalization rates differ between COPD pa-
tients who switched therapy and/or have bettermedical management in theMedi-
care population. METHODS: This is a cross-sectional retrospective study of COPD
Medicare patients between January 2006 and December 2008. Eligible patients had
at least one claim for COPD in 2006 as 1st diagnosis and were also continuously
eligible for parts A, B and D during the study period. Patients enrolled in Medicare
Advantage, diagnosed with asthma and younger than 65 years old were excluded.
Therapy switch was defined as patient switching all drugs taken in the previous
year. Probability of hospitalization was estimated using a logit model with regres-
sors of age, gender, race, previous hospitalization, previous therapy, previous
COPD test, physician visits and comorbidities. RESULTS: A total of 44,933 patients
were included in the study. The average age was 77.8 years old. A majority of the
patients were female (64.1%), and white (89.8%). Congestive heart failure, diabetes
and hyperlipidemia were the most common comorbidities. The most frequently
prescribed therapy was oxygen (around 30%), followed by Short-Acting Beta Ago-
nists (14%). Patientswho received greater COPDmedicalmanagement as defined as
COPD therapy (including higher OCS use), number spirometry tests and physician
visits for COPDwere associatedwith decreased likelihood of hospitalization in 2008
(p-value  0.05). Moreover, therapy discontinuation, new therapy starters, weight
loss, hyperlipidemia, liver disease, coagulapathy and renal failure were associated
with higher COPD hospitalization risk while depression, congestive heart failure
with lower hospitalization risk (p-values  0.05). Also, in this population around
21% visited a specialist physician, 14% had ER visit and 20% were hospitalized for
COPD in 06, 07, 08. CONCLUSIONS: The findings suggest that patients maintaining
the same therapy across years and patients with greater COPDmedical management
are less likely to be hospitalized compared to patients with worse disease control.
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OBJECTIVES: In Korea, the price of new drug has been decided through price ne-
gotiation after evaluation for reimbursement in decision process since 2007. The
price of new drug was negotiated considering price of reference drugs, budget
impact analysis, substitution rate, etc. This study attempted to analyze states of
new drugs’ listing and identify influential factor in reimbursement and pricing
negotiation, and to analyze satisfaction of pharmaceutical companies concerned
on price negotiation. METHODS: Data on reimbursement for 3 years (2007.01.01-
2009.12.31) were obtained from the agency’s website posting results for reimburse-
ment determination, and Korean Ministry of Health and Welfare Affairs’ drug no-
tification on the results of price negotiation. The questionnaire consisting of
negotiation guideline (article 10, 11) and satisfaction was made and used to collect
responses of pharmaceutical companies’ working group. The e-mail for the survey
was sent out to 31 companies, survey response rate was 71%. RESULTS: Cost-
effectiveness (84.5%) was affecting factor of reimbursement in decision process.
The lead time of reimbursement and pricing was around 12.8months. The listing
price was determined as average 67% compared to application price, application
price was cut by approximately 20% in decision-making of reimbursement, after
that, that price was cut by approximately 17% in price negotiation process. In
negotiation process, the price of reference drugs had great influence on results of
negotiation. Mainly the lowest price in therapeutic area was referenced in negoti-
ation process. Negative perceptions on process of pricing negotiation were found
especially predictability of price and appreciating its value, and the needs for de-
tailed guideline have been mentioned. CONCLUSIONS: The satisfaction of negoti-
ation processwas very negative, the reasonwas that Positive list systemmade new
drugs’ listingmore difficult and lengthened the lead time of listing. To enhance the
negotiation process, it is necessary to develop the detailed guideline on process of
price negotiation.
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